Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-Label Dose-Escalation Study to Evaluate the Tolerability, DLT, Pharmacokinetics, and Preliminary Efficacy of HF1K16 in Patients With Refractory Solid Tumors

Next Previous
Trial Profile

A Phase 1 Open-Label Dose-Escalation Study to Evaluate the Tolerability, DLT, Pharmacokinetics, and Preliminary Efficacy of HF1K16 in Patients With Refractory Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tretinoin (Primary)
  • Indications Adenocarcinoma; Cholangiocarcinoma; Colon cancer; Glioblastoma; Glioma; Ovarian cancer; Small cell lung cancer; Solid tumours; Thymic epithelial tumour
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors HighField Biopharmaceuticals

Most Recent Events

  • 30 Apr 2025 Results assessing the safety and preliminary efficacy of ATRA liposomes (HF1K16) in last-stage solid tumor patients presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 16 Sep 2024 According to a HighField Biopharmaceuticals media release, as of Sept 1, 2024, 19 patients having Grade II, III and IV tumors have been enrolled.
  • 16 Sep 2024 According to a HighField Biopharmaceuticals media release, the Company presented preliminary safety and efficacy findings at the European Society of Medical Oncology (ESMO) Congress in Barcelona, Spain, September 13 -17, 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top